tepadina
adienne s.r.l. s.u. - thiotepa - transplantácia hematopoetických kmeňových buniek - antineoplastické činidlá - v kombinácii s inými chemoterapia liekov:s alebo bez celkovej telesnej ožiareniu (tbi), ako je klimatizácia liečba pred allogeneic alebo autológne hematopoetickú predok buniek transplantácia (hpct) v hematologické ochorenia u dospelých a pediatrických pacientov, keď vysoké dávky chemoterapie s hpct podpory je vhodné pre liečbu solídne nádory u dospelých a pediatrických pacientov. navrhuje sa, aby tepadina musí byť predpísané lekármi zažil v klimatizácia liečba pred hematopoetickú predok bunky transplantáciu.
perindopril fmk 4 mg
farmak international sp. z o.o., poľsko - perindopril - 58 - hypotensiva
perindopril fmk 8 mg
farmak international sp. z o.o., poľsko - perindopril - 58 - hypotensiva
epirubicin accord 2 mg/ml
accord healthcare polska sp. z o.o., poľsko - epirubicín - 44 - cytostatica
cyklofosfamid accord 1 000 mg prášok na injekčný/infúzny roztok
accord healthcare polska sp. z o.o., poľsko - cyklofosfamid - 44 - cytostatica
cyklofosfamid accord 500 mg prášok na injekčný/infúzny roztok
accord healthcare polska sp. z o.o., poľsko - cyklofosfamid - 44 - cytostatica
cyklofosfamid accord 2000 mg prášok na injekčný /infúzny roztok
accord healthcare polska sp. z o.o., poľsko - cyklofosfamid - 44 - cytostatica
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastické činidlá - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.
opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanóm - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.